Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 360Neoplasms 255Carcinoma, Non-Small-Cell Lung 199Colorectal Neoplasms 183Lung Neoplasms 152Prostatic Neoplasms 151Carcinoma, Hepatocellular 128Leukemia, Myeloid, Acute 96Pancreatic Neoplasms 86Multiple Myeloma 84Neoplasm Metastasis 74Recurrence 71Uterine Cervical Neoplasms 69Rectal Neoplasms 68Stomach Neoplasms 65Ovarian Neoplasms 65Triple Negative Breast Neoplasms 60Squamous Cell Carcinoma of Head and Neck 57Head and Neck Neoplasms 54Glioblastoma 54Brain Neoplasms 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Small Cell Lung Carcinoma 50Endometrial Neoplasms 47Melanoma 44Esophageal Neoplasms 43Disease 43Colonic Neoplasms 42Hematologic Neoplasms 41Glioma 40

Interventions

trastuzumab deruxtecan 1Isovaleryl-CoA Dehydrogenase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × HER2 Overexpression × 1 year × Clear all
NCT07035353 2025-06-25

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting
200 enrolled
Breast

HER2 Overexpression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡